301 related articles for article (PubMed ID: 21677329)
21. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease.
Li W; Zheng L; Sheng C; Cheng X; Qing L; Qu S
Lipids Health Dis; 2011 Apr; 10():49. PubMed ID: 21477300
[TBL] [Abstract][Full Text] [Related]
22. Pentoxifylline attenuates methionine- and choline-deficient-diet-induced steatohepatitis by suppressing TNF-α expression and endoplasmic reticulum stress.
Chae MK; Park SG; Song SO; Kang ES; Cha BS; Lee HC; Lee BW
Exp Diabetes Res; 2012; 2012():762565. PubMed ID: 22319522
[TBL] [Abstract][Full Text] [Related]
23. Non-alcoholic steatohepatitis with normal aminotransferase values.
Uslusoy HS; Nak SG; Gülten M; Biyikli Z
World J Gastroenterol; 2009 Apr; 15(15):1863-8. PubMed ID: 19370784
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and histological features of non-alcoholic fatty liver disease].
Shi JP; Xun YH; Hu CB; Zhang L; Liu H; Lou GQ; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):812-6. PubMed ID: 19958638
[TBL] [Abstract][Full Text] [Related]
25. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
[TBL] [Abstract][Full Text] [Related]
26. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin.
Gonciarz M; Gonciarz Z; Bielanski W; Mularczyk A; Konturek PC; Brzozowski T; Konturek SJ
J Physiol Pharmacol; 2010 Dec; 61(6):705-10. PubMed ID: 21224501
[TBL] [Abstract][Full Text] [Related]
27. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Georgescu EF; Georgescu M
J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
[TBL] [Abstract][Full Text] [Related]
29. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
[TBL] [Abstract][Full Text] [Related]
30. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
[TBL] [Abstract][Full Text] [Related]
31. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study.
Geier A; Eichinger M; Stirnimann G; Semela D; Tay F; Seifert B; Tschopp O; Bantel H; Jahn D; Marques Maggio E; Saleh L; Bischoff-Ferrari HA; Müllhaupt B; Dufour JF
Scand J Gastroenterol; 2018 Sep; 53(9):1114-1120. PubMed ID: 30270688
[TBL] [Abstract][Full Text] [Related]
32. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.
Du J; Ma YY; Yu CH; Li YM
World J Gastroenterol; 2014 Jan; 20(2):569-77. PubMed ID: 24574727
[TBL] [Abstract][Full Text] [Related]
33. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study.
Hasegawa T; Yoneda M; Nakamura K; Makino I; Terano A
Aliment Pharmacol Ther; 2001 Oct; 15(10):1667-72. PubMed ID: 11564008
[TBL] [Abstract][Full Text] [Related]
34. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study.
Merat S; Malekzadeh R; Sohrabi MR; Sotoudeh M; Rakhshani N; Sohrabpour AA; Naserimoghadam S
J Hepatol; 2003 Apr; 38(4):414-8. PubMed ID: 12663231
[TBL] [Abstract][Full Text] [Related]
35. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
36. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
Adams LA; Zein CO; Angulo P; Lindor KD
Am J Gastroenterol; 2004 Dec; 99(12):2365-8. PubMed ID: 15571584
[TBL] [Abstract][Full Text] [Related]
37. Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis.
Suzuki A; Lymp J; St Sauver J; Angulo P; Lindor K
Liver Int; 2006 Dec; 26(10):1209-16. PubMed ID: 17105586
[TBL] [Abstract][Full Text] [Related]
38. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.
Akriviadis E; Botla R; Briggs W; Han S; Reynolds T; Shakil O
Gastroenterology; 2000 Dec; 119(6):1637-48. PubMed ID: 11113085
[TBL] [Abstract][Full Text] [Related]
39. Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia.
Coimbra R; Porcides RD; Melbostad H; Loomis W; Tobar M; Hoyt DB; Wolf P
Surg Infect (Larchmt); 2005; 6(1):73-85. PubMed ID: 15865553
[TBL] [Abstract][Full Text] [Related]
40. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis.
Satapathy SK; Garg S; Chauhan R; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
Am J Gastroenterol; 2004 Oct; 99(10):1946-52. PubMed ID: 15447754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
